Deferoxamine Retinopathy: Protecting Your Vision
Understanding Deferoxamine Retinopathy
Deferoxamine (DFO) is an iron chelation drug. It works by binding to excess iron in the body and allowing it to be removed through urine or stool. It is most often given by subcutaneous infusion (slow injection under the skin) or intravenously (through a vein).
People who receive frequent blood transfusions, such as those with thalassemia, sickle cell disease, or myelodysplastic syndrome, often develop iron overload. Without chelation therapy, excess iron can damage the heart, liver, and other organs. Deferoxamine is one of three iron chelators commonly used. The others are deferiprone and deferasirox (Exjade).
The exact way deferoxamine damages the eye is not fully understood. Research suggests the drug strips essential trace metals, particularly zinc and copper, from retinal tissue. These metals play important roles in the visual cycle, phototransduction (how light is converted to signals), and neurotransmission in the retina.
Histologic studies have shown that deferoxamine causes changes resembling cell death in the retinal pigment epithelium (RPE), a layer of cells that nourishes and supports the photoreceptors. These changes include swelling and calcification of mitochondria, loss of surface structures called microvilli, and breakdown of the cell membrane. Damaged RPE cells can swell, detach, and project into the space beneath the retina.
Deferoxamine retinopathy primarily targets the RPE, Bruch membrane (a thin barrier beneath the RPE), and the photoreceptor layer. Damage can extend from the area surrounding the central macula out to the peripheral retina. Interestingly, the very center of the macula, called the foveola, is often spared in earlier stages of the disease.
In some cases, deferoxamine can also cause optic neuropathy, which is damage to the optic nerve. This may present differently from retinopathy and can occur on its own or alongside retinal changes.
Who Is Affected and Risk Factors
The people most likely to develop deferoxamine retinopathy are those with conditions requiring regular blood transfusions over many years. Beta-thalassemia major is the most commonly associated condition. Patients with sickle cell disease, myelodysplastic syndrome, and other chronic anemias that lead to iron overload may also be at risk.
One study confirmed deferoxamine retinopathy in 20 patients with beta-thalassemia, all of whom had received deferoxamine for a minimum of 10 years (AAO, 2018). The mean duration of treatment in these patients was 32.7 years, with daily doses ranging from 1.5 grams to 4.5 grams (AAO, 2018).
Several factors can raise the likelihood of developing retinal toxicity from deferoxamine.
- Higher doses of deferoxamine
- Longer duration of chelation therapy
- Intravenous administration, which delivers the drug more rapidly than subcutaneous infusion
- Electrolyte imbalances, particularly low zinc or copper levels
- Possible iron-related damage to the blood-retinal barrier, the protective boundary between the bloodstream and the retina
Deferoxamine retinopathy appears to be uncommon, though it may be underdiagnosed. In a study of 84 pediatric patients receiving deferoxamine, ocular toxicity was found in only one patient, representing an incidence of 1.2% (Retina, 2008). The risk may be higher in adults who have used the drug for decades. Patients with sickle thalassemia may also develop angioid streaks, with one study reporting a 10% incidence of angioid streaks in 58 cases (PMC, 2018).
Signs and Symptoms
Deferoxamine retinopathy can develop gradually, and early stages may not cause noticeable symptoms. As the condition progresses, patients may experience several visual changes.
- Decreased visual acuity (blurry vision)
- Night blindness or difficulty seeing in dim light
- Changes in color vision, such as colors appearing washed out or distorted
- Central blind spots, called scotomas
- Difficulty reading
- Metamorphopsia (straight lines appearing wavy or distorted)
Some patients develop signs of retrobulbar optic neuropathy, meaning the optic nerve is affected behind the eye. In one case series, six patients presented with central scotomas and color vision abnormalities that were initially thought to be optic nerve problems rather than retinal toxicity. These cases highlight the importance of thorough testing when visual symptoms arise during deferoxamine therapy.
A retina specialist may observe patchy depigmentation of the RPE, particularly in the equatorial region and the posterior pole of the eye. Ten patients in one study showed pattern dystrophy-like RPE changes in the macula, including butterfly-shaped patterns, fundus flavimaculatus-like changes, fundus pulverulentus patterns, and vitelliform deposits (AAO, 2018). These changes are visible on clinical examination and become even more apparent with advanced imaging.
Diagnosis and Testing
Fundus autofluorescence (FAF) imaging has become a key tool for detecting deferoxamine retinopathy. FAF captures the natural fluorescence of a substance called lipofuscin in the RPE. When RPE cells are damaged or stressed, abnormal patterns of autofluorescence appear.
Research has shown that changes on FAF imaging are often more widespread than what is visible during a standard eye examination. This makes FAF a rapid and reliable method both for screening high-risk patients and for tracking the condition over time.
Spectral-domain optical coherence tomography (SD-OCT) provides detailed cross-sectional images of the retina. In deferoxamine retinopathy, SD-OCT can reveal disruption of the photoreceptor layer, changes at the junction between the inner and outer segments of photoreceptors, and accumulated hyper-reflective deposits in the choroid, RPE, and photoreceptor layers. Follow-up SD-OCT imaging helps track whether damage is stable or progressing.
Electroretinography (ERG) measures the electrical responses of the retina to light. In deferoxamine retinopathy, ERG may show decreased central cone responses, reduced rod responses, or both. This test can help confirm that the retina is functionally impaired and can also be used to monitor recovery after the drug is stopped or changed.
Fluorescein angiography, which uses a special dye to photograph retinal blood vessels, may show diffuse RPE fluorescence. This finding can be a marker for active retinopathy at both initial diagnosis and during recurrence. It may also appear before visible pigment changes develop. Near-infrared reflectance (NIR) imaging on a confocal scanning laser ophthalmoscope can provide additional detail about RPE and subretinal changes.
Patients beginning long-term deferoxamine therapy should have a comprehensive baseline eye examination. This should include visual acuity testing, color vision testing, and retinal imaging. Regular follow-up examinations, typically every six to twelve months, allow early detection of toxicity before significant vision loss occurs.
Treatment Options
The most important step in treating deferoxamine retinopathy is discontinuing or reducing the dose of the drug. In published case series, vision improved in the majority of eyes after deferoxamine was stopped. Optic neuropathy resolved in all reported cases. However, not all eyes recovered to their original level of vision. Some eyes did not regain their pretreatment visual acuity, underscoring the importance of early detection.
In one case, a patient with central blurriness, retinal pigmentary changes, and decreased central responses on ERG experienced complete reversal of these findings after switching from intravenous to subcutaneous therapy at a reduced dose.
When deferoxamine must be discontinued, patients still need iron chelation to prevent organ damage from iron overload. The two main alternatives are deferasirox (an oral chelator) and deferiprone (also taken by mouth). In one reported case, a patient was switched from deferoxamine to oral deferasirox and deferiprone. Six weeks later, best-corrected vision improved to 20/60 in the right eye and 20/25 in the left eye, and color vision also improved.
The decision to switch chelators requires close coordination between a retina specialist and a hematologist. The hematologist ensures that iron levels remain controlled, while the retina specialist monitors the eyes for improvement or stability.
Patients who develop deferoxamine retinopathy require ongoing retinal monitoring even after the drug is stopped or changed. In two reported cases, patients who were switched to alternative chelation therapy were followed every three months for two and four years respectively. Their visual acuity remained stable and no anatomic changes were seen on OCT during follow-up. Both patients had normal cone and rod responses on full-field ERG and were able to continue their prescribed chelation therapy.
What to Expect
The outlook for deferoxamine retinopathy depends heavily on how early the condition is detected and how quickly the drug is discontinued or adjusted. Many patients experience meaningful improvement in visual acuity, color vision, and ERG findings. Optic neuropathy cases have shown particularly favorable recovery.
However, patients who continue deferoxamine after retinopathy is detected risk further RPE and retinal injury. Continued use can lead to progressive visual deterioration that may not be fully reversible.
Patients who have had deferoxamine retinopathy should understand that their retinas may remain more vulnerable than those of the general population. Even with improvement, some residual RPE changes may persist on imaging. Regular follow-up visits help ensure that any changes are caught early. If alternative chelation therapy is used, the retina specialist will continue to check for any new signs of toxicity, as other chelators may carry their own risks.
Managing deferoxamine retinopathy requires teamwork between multiple specialists. A hematologist manages the underlying blood disorder and iron overload. A retina specialist monitors the eyes and guides decisions about when to stop, reduce, or change chelation therapy. Patients should make sure both specialists are aware of their complete treatment history and current medications.
When to See a Retina Specialist
Any patient about to begin long-term deferoxamine therapy should see a retina specialist for a baseline examination. This includes visual acuity measurement, color vision assessment, and retinal imaging with OCT and fundus autofluorescence. Establishing a baseline allows the specialist to detect even subtle changes during future visits.
Patients on deferoxamine should contact a retina specialist promptly if they notice any of the following: blurry or decreased central vision, difficulty seeing at night, changes in how colors appear, blind spots in the center of their vision, or wavy or distorted lines. Early evaluation and intervention give the best chance of preserving vision.
Even without symptoms, patients on long-term deferoxamine therapy benefit from regular retinal examinations. Many specialists recommend screening every six to twelve months. Fundus autofluorescence imaging can detect RPE changes before they become visible on standard examination, making it a valuable part of routine monitoring.
Questions and Answers
In many cases, yes. When deferoxamine is stopped or the dose is reduced early, visual acuity, color vision, and retinal function can improve significantly. Optic neuropathy caused by deferoxamine has resolved in all reported cases. However, some patients do not fully recover their previous level of vision, especially if the condition was not caught early. This is why regular screening is so important for anyone on long-term deferoxamine therapy.
Iron chelation is still necessary to protect your heart, liver, and other organs from iron overload. If deferoxamine is causing retinal toxicity, a hematologist can switch you to an alternative oral chelator such as deferasirox or deferiprone. These medications work differently and may not carry the same risk to the retina. Your retina specialist and hematologist will work together to find the safest approach for your situation.
Most retina specialists recommend a comprehensive eye examination every six to twelve months during deferoxamine therapy. This should include visual acuity testing, color vision testing, and retinal imaging such as fundus autofluorescence and optical coherence tomography. A baseline examination before starting therapy is also recommended so that any future changes can be compared to your starting point.
Children can develop deferoxamine-related ocular toxicity, though it appears to be uncommon. In a study of 84 pediatric patients, only one child (1.2%) showed signs of ocular toxicity (Retina, 2008). However, children with thalassemia or other transfusion-dependent conditions may use deferoxamine for many years or decades, so cumulative exposure remains a concern. Pediatric patients on long-term chelation therapy should receive regular eye screenings.
Fundus autofluorescence (FAF) imaging is considered the most sensitive screening tool for deferoxamine retinopathy. It can detect RPE damage that is not yet visible during a standard eye examination. Spectral-domain optical coherence tomography (SD-OCT) provides detailed cross-sectional views of the retinal layers and can show disruption of photoreceptors and deposits in the RPE and choroid. Together, these two tests give a comprehensive picture of retinal health and are recommended for both initial screening and ongoing monitoring.